### New High-Dose Eylea for Diabetic Macular Edema The U.S. FDA has approved a new, higher-dose version of the drug aflibercept, known as Eylea HD, which can be administered less frequently to patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). This new 8 mg dose can replace the current 2 mg formula, allowing for longer intervals between injections. This is particularly beneficial for elderly patients who may have difficulty adhering to frequent treatment schedules. Clinical trials have shown that the higher dose is just as effective as the lower dose, with patients maintaining their vision with fewer injections. This advancement is expected to improve patient compliance and reduce the burden on both patients and healthcare providers.